Dr. Krishnan has successfully grown the City of Hope multiple myeloma program to be the largest in southern California, with approaching 500 new patients seen per year, and has led the development of a large, diverse clinical trial portfolio of more than 15 active Phase I/II trials for all phases of multiple myeloma, now under the auspices of our recently established Judy and Bernard Briskin Center for Multiple Myeloma. She has worked to establish a strong preclinical translational program in myeloma, including our own myeloma CAR T cell program, and has led several unique trials with antibody directed therapy. On a national level, Dr. Krishnan is also the former multiple myeloma chair of the BMT CTN and current member of the CTN myeloma team, and served as national co PI of three large transplantation studies including the current SWOG/CTN trial of daratumumab/lenalidomide versus lenalidomide maintenance with an MRD-directed treatment strategy. She has been a long-standing gy, Dr. Krishnan has belonged to the American Society of Hematology communications committee for several years. SHe has been a leader in novel therapeutics in myeloma including serving as PI for early trials of Bispecific antibodies.